– UK, Southampton – Synairgen plc (LON: SNG), the respiratory company today announced the appointment of Dr. Flic Gabbay to its Board as a Non-Executive Director.
“Flic is highly experienced with a deep understanding of drug development and pharmaceutical medicine. Over her distinguished career, she has gained invaluable experience in supporting companies to progress their candidate drugs through the clinic and we look forward to benefitting from her insights as we continue the clinical development of SNG001,” said Board Chair, Simon Shaw.
Concurrently, the company also announced that Theodora Harold is stepping down from the Board with immediate effect.
About Dr. Felicity Gabbay
Dr. Felicity Gabbay has extensive experience within the life sciences sector including holding several senior and CEO positions in big pharma, biotech, and CROs in both Europe and North America. As Founder and Managing Partner at TranScrip LLP, founded in 2008, she has overseen drug development work with companies at all stages of the drug development cycle, securing private equity investment and the acquisition of Real Regulatory.
Starting her career as a medical doctor, she held various medical posts across Europe before moving into the biotechnology sector. She is the current President of the Faculty of Pharmaceutical Medicine for the three Royal Colleges of Physicians.
In 2020, Flic was awarded the Fellowship of the Academy of Medical Science and is passionate about bringing pharmaceutical medicine into mainstream medical science and its application to public health.
She completed a BSc in Pharmacology and a Bachelor of Medicine and Surgery degree at the University of Manchester.
Flic Gabbay said: “I am pleased to join the Board of Synairgen as it works towards the next milestones for SNG001 as a potential therapeutic for severe respiratory viral infections. I look forward to working closely with the Synairgen Management team and Board on the next steps for the Company’s clinical development.”
Synairgen is a UK-based respiratory company focused on drug discovery, development, and commercialization. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for treating severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral therapy delivered directly into the lungs. SNG001 has been granted Fast Track status by the US Food and Drug Administration. Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies, and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LON: SNG).
For more information: https://www.synairgen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.